IOS-1002
Phase 1- Indications
- Advanced solid tumors
Company intelligence / Profile preview
Immune System Therapeutics
Sydney, New South Wales, Australiaistl.com.au ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
As of the early 2010s, Immune System Therapeutics developed monoclonal antibodies for blood cancers and autoimmune diseases. Its lead candidate, MDX‑1097 targeting kappa myeloma antigen for multiple myeloma, showed encouraging safety and efficacy signals in early clinical trials and entered Phase 2 studies. The company also held robust patents on its drug class but has not reported recent clinical results publicly since that time.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Monoclonal antibodyAntibody
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Immune System Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immune System Therapeutics.